| Long-lasting cognitive deficits resulting from adolescent nicotine exposure in rats DS Counotte, S Spijker, LH Van de Burgwal, F Hogenboom, ... Neuropsychopharmacology 34 (2), 299-306, 2009 | 188 | 2009 |
| Overcoming challenges for designing and implementing the One Health approach: A systematic review of the literature CS Ribeiro, LHM van de Burgwal, BJ Regeer One Health 7, 100085, 2019 | 114 | 2019 |
| A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: valorisation and improving the tech transfer cycle M Van den Nieuwboer, LHM Van de Burgwal, E Claassen PharmaNutrition 4 (1), 9-18, 2016 | 67 | 2016 |
| Challenges and best practices for big data-driven healthcare innovations conducted by profit–non-profit partnerships–a quantitative prioritization ER Witjas-Paalberends, LPM van Laarhoven, LHM van de Burgwal, ... International Journal of Healthcare Management 11 (3), 171-181, 2018 | 43 | 2018 |
| How ownership rights over microorganisms affect infectious disease control and innovation: a root-cause analysis of barriers to data sharing as experienced by key stakeholders CS Ribeiro, MY van Roode, GB Haringhuizen, MP Koopmans, ... PloS one 13 (5), e0195885, 2018 | 40 | 2018 |
| Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective MB van der Waal, J Flach, PD Browne, I Besseling-van der Vaart, ... Pharmanutrition 7, 100139, 2019 | 27 | 2019 |
| Blockchain-facilitated sharing to advance outbreak R&D MB van der Waal, C dos S. Ribeiro, M Ma, GB Haringhuizen, E Claassen, ... Science 368 (6492), 719-721, 2020 | 25 | 2020 |
| Accelerating microbiota product development: the Societal Impact Value Cycle as a conceptual model to shape and improve public-private valorization processes LHM Van de Burgwal, MB Van der Waal, E Claassen PharmaNutrition 6 (4), 157-168, 2018 | 24 | 2018 |
| Aiming for impact: Differential effect of motivational drivers on effort and performance in knowledge valorisation LHM Van De Burgwal, R Hendrikse, E Claassen Science and Public Policy 46 (5), 747-762, 2019 | 22 | 2019 |
| Incentives for knowledge valorisation: a European benchmark LHM van de Burgwal, A Dias, E Claassen The Journal of Technology Transfer 44 (1), 1-20, 2019 | 21 | 2019 |
| The Nagoya Protocol on Access to Genetic Resources and Benefit Sharing: Best practices for users of Lactic Acid Bacteria J Flach, CS Ribeiro, MB van der Waal, RX van der Waal, E Claassen, ... PharmaNutrition 9, 100158, 2019 | 17 | 2019 |
| Hybrid business models for ‘Organ-on-a-Chip’technology: The best of both worlds LHM van de Burgwal, P van Dorst, H Viëtor, R Luttge, E Claassen PharmaNutrition 6 (2), 55-63, 2018 | 16 | 2018 |
| Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature LHM van de Burgwal, AMG Neevel, C Pittens, A Osterhaus, CE Rupprecht, ... Zoonoses and public health 64 (8), 599-611, 2017 | 16 | 2017 |
| On the Verge of a Catastrophic Collapse? The Need for a Multi-Ecosystem Approach to Microbiome Studies O Larsen, L van de Burgwal Frontiers in Microbiology 12, 2021 | 15 | 2021 |
| Towards improved process efficiency in vaccine innovation: The Vaccine Innovation Cycle as a validated, conceptual stage-gate model LHM Van de Burgwal, CDS Ribeiro, MB Van der Waal, E Claassen Vaccine 36 (49), 7496-7508, 2018 | 14 | 2018 |
| Ebola: public-private partnerships LA Reperant, LHM Burgwal, E Claassen, A Osterhaus Science 346 (6208), 433-434, 2014 | 14 | 2014 |
| Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials AM Van der Geest, I Schukking, RJM Brummer, LHM van de Burgwal, ... Beneficial Microbes 13 (3), 183-194, 2022 | 13 | 2022 |
| Barriers influencing vaccine development timelines, identification, causal analysis, and prioritization of key barriers by KOLs in general and Covid-19 vaccine R&D M Janse, T Brouwers, E Claassen, P Hermans, L Van de Burgwal Frontiers in public health 9, 612541, 2021 | 13 | 2021 |
| European General Practitioners perceptions on probiotics: Results of a multinational survey AM van der Geest, J Flach, E Claassen, AW Sijlmans, ... PharmaNutrition 11, 100178, 2020 | 13 | 2020 |
| Probiotics for the management of infectious diseases: reviewing the state of the art C Wiegers, LHM Van de Burgwal, OFA Larsen Frontiers in Microbiology 13, 877142, 2022 | 12 | 2022 |
Dr. Mark B. van der WaalPhD, Vrije Universiteit AmsterdamVerified email at vu.nl
